As SVP and Head of the Immuno-oncology (I-O) franchise at MedImmune/AstraZeneca, David Berman is responsible for the strategy and execution of our late stage I-O program. Over his career, David has had the pleasure of moving back and forth between early and late stage development. Prior to his current role, David was head of the early stage oncology program at MedImmune. Before joining our company, and over a 10-year span, he led development of multiple different oncology biologics and small molecules spanning from pre-clinical through commercialization.
David is proud to have worked on I-O initially in academia and then throughout his entire 13-year industry career. As a pathologist at the National Cancer Institute, he collaborated on mechanisms of IO mediated toxicity and activity. In industry, he led translational and clinical programs for multiple IO mechanisms and was the global clinical lead for the first approved IO checkpoint inhibitor.
Earlier in his career, he completed his PhD in the Laboratory of Dr. Alfred G. Gilman, the 1994 Nobel laureate for his discovery of G-proteins. .
I-O presents potential new options for patients with a wide range of cancer types. As we continue to advance our understanding of both the immune system and tumour resistance he is pleased that we as a company are committed to discovering where this new knowledge leads us to new potential therapeutic options for patients.
The only thing more fun than learning new insights into cancer immunity is translating this into new medicines for patients.
SVP and Head of the Immuno-oncology (I-O) franchise at MedImmune/AstraZeneca, responsible for the strategy and execution of our late stage I-O program
Worked both in academia and industry on the first I-O treatment to market.
Led early development for both several small molecules and, designed and led multiple biomarker trials in the search for new I-O treatments
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.